Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | IAPP | P10997 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424396 | 0.83 | TDP1 (0.47) | TDP1ALDH1A1FFAR3IAPPCES2 | |
| SCHEMBL840557 | 0.81 | ALDH1A1 (0.45) | TDP1ALDH1A1FFAR3IAPP | |
| SCHEMBL31016294 | 0.80 | TDP1 (0.50) | TDP1ALDH1A1FFAR3IAPPCES2 | |
| SCHEMBL21078338 | 0.79 | TDP1 (0.43) | TDP1ALDH1A1FFAR3IAPPHSD17B10 | |
| SCHEMBL27511799 | 0.79 | TDP1 (0.43) | TDP1ALDH1A1FFAR3IAPP | |
| SCHEMBL11533113 | 0.78 | ALDH1A1 (0.33) | TDP1ALDH1A1LMNAHSD17B10CES2 | |
| SCHEMBL17481554 | 0.77 | ACLY (0.42) | TDP1ALDH1A1FFAR3 | |
| SCHEMBL2184017 | 0.77 | TDP1 (0.41) | TDP1ALDH1A1FFAR3 | |
| SCHEMBL12344369 | 0.77 | TDP1 (0.41) | TDP1 | |
| SCHEMBL8896096 | 0.77 | TDP1 (0.41) | TDP1ALDH1A1FFAR3LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TDP1 1003/4885ALDH1A1 3992/4885FFAR3 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.